Status | Study |
Completed |
Study Name: Scleroderma ARFI Imaging of the Skin Condition: Scleroderma Date: 2013-11-26 Interventions: Device: ARFI-SVI Ultrasound Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Partic |
Recruiting |
Study Name: Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Condition: Localized Scleroderma Date: 2013-09-05 Interventions: Device: Fractional carbon dioxide laser |
Recruiting |
Study Name: Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository Condition: Scleroderma, Localized Morphea Date: 2013-02-25 Interventions: Other: Morphea Other Names: Scleroderma, Localized Scleroderma |
Completed |
Study Name: Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Condition: Scleroderma, Localized Morphea Date: 2013-02-22 Interventions: Procedure: UVA-1 Phototherapy Procedure: P |
Completed |
Study Name: Morbidity and Mortality Follow Up for the Scleroderma Lung Study Condition: Scleroderma Date: 2013-01-04 Interventions: Other: Followup survey |
Completed |
Study Name: The CARRA Registry Condition: Juvenile Idiopathic Arthritis Systemic Lupus Erythematosus Date: 2012-09-28 |
Recruiting |
Study Name: Scleroderma Registry & Repository at the Hospital for Special Surgery Condition: Scleroderma Date: 2012-08-01 |
Recruiting |
Study Name: Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Condition: Scleroderma Date: 2012-03-05 Interventions: Other: Blood sample blood sample, venous blood, about 10 ml will be drawn from participants |
Terminated |
Study Name: Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Condition: Scleroderma Date: 2012-03-01 Interventions: Drug: Imatinib mesylate 200 mg |
Completed |
Study Name: A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Condition: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) Date: 2009-07-09 Interventions: Drug: Rituximab Mabthera, Rituximab 1000 mg I.V. |